Targeting tumor suppressor genes for cancer therapy

BioEssays

Volumn 37, Issue 12, 2015, Pages 1277-1286

  Liu, Yunhua ^a   Hu, Xiaoxiao ^b   Han, Cecil ^a   Wang, Liana ^a   Zhang, Xinna ^a   He, Xiaoming ^c   Lu, Xiongbin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HUNAN UNIVERSITY   (China)

^c The Ohio State University   (United States)

Author keywords

Cancer genomics; Druggability; Gene copy loss; Gene therapy; Synthetic lethality; Target therapy; Tumor suppressor

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; PROTEIN P53; VIRUS VECTOR; ANTINEOPLASTIC AGENT;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL; CANCER GENETICS; CLINICAL TRIAL (TOPIC); DNA DAMAGE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE TARGETING; GENOMIC INSTABILITY; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; TUMOR SUPPRESSOR GENE; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; GENOMICS; MUTATION; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GENES, TUMOR SUPPRESSOR; GENOMICS; HUMANS; MUTATION; NEOPLASMS;

EID: 84947484618     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201500093     Document Type: Article

References (129)

1. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-74.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, et al. 2013. Cancer genome landscapes. Science 339: 1546-58.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-21.
4. Forbes SA, Bindal N, Bamford S, Cole C, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945.
5. Stratton MR. 2011. Exploring the genomes of cancer cells: progress and promise. Science 331: 1553-8.
6. Chin L, Hahn WC, Getz G, Meyerson M. 2011. Making sense of cancer genomic data. Genes Dev 25: 534-55.
7. Hanash S, Taguchi A. 2010. The grand challenge to decipher the cancer proteome. Nat Rev Cancer 10: 652-60.
8. Wills QF, Mead AJ. 2015. Application of single-cell genomics in cancer: promise and challenges. Hum Mol Genet 24: R74-84.
9. Prahallad A, Bernards R. 2015. Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene, in press, DOI: 10.1038/onc.2015.151.
10. Lewin J, Siu LL. 2015. Cancer genomics: the challenge of drug accessibility. Curr Opin Oncol 27: 250-7.
11. Ciccia A, Elledge SJ. 2010. The DNA damage response: making it safe to play with knives. Mol Cell 40: 179-204.
12. Skibinski A, Kuperwasser C. 2015. The origin of breast tumor heterogeneity. Oncogene, in press, DOI: 10.1038/onc.2014.475.
13. Gerdes MJ, Sood A, Sevinsky C, Pris AD, et al. 2014. Emerging understanding of multiscale tumor heterogeneity. Front Oncol 4: 366.
14. Ramos P, Bentires-Alj M. 2015. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 34: 3617-26.
15. Easwaran H, Tsai HC, Baylin SB. 2014. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54: 716-27.
16. Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, et al. 2015. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods 12: 423-5.
17. Brannon AR, Vakiani E, Sylvester BE, Scott SN, et al. 2014. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 15: 454.
18. Siroy AE, Boland GM, Milton DR, Roszik J, et al. 2015. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135: 508-15.
19. Oesper L, Satas G, Raphael BJ. 2014. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics 30: 3532-40.
20. Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GR, et al. 2013. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods 10: 723-9.
21. Ding L, Wendl MC, McMichael JF, Raphael BJ. 2014. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 15: 556-70.
22. Raphael BJ, Dobson JR, Oesper L, Vandin F. 2014. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med 6: 5.
23. Patel MN, Halling-Brown MD, Tym JE, Workman P, et al. 2013. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12: 35-50.
24. Begley CG, Ellis LM. 2012. Drug development: raise standards for preclinical cancer research. Nature 483: 531-3.
25. Prinz F, Schlange T, Asadullah K. 2011. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10: 712.
26. Ng PC, Henikoff S. 2003. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-4.
27. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, et al. 2010. A method and server for predicting damaging missense mutations. Nat Methods 7: 248-9.
28. Reva B, Antipin Y, Sander C. 2011. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39: e118.
29. Shihab HA, Gough J, Cooper DN, Day IN, et al. 2013. Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics 29: 1504-10.
30. Shihab HA, Gough J, Cooper DN, Stenson PD, et al. 2013. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 34: 57-65.
31. Carter H, Chen S, Isik L, Tyekucheva S, et al. 2009. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 69: 6660-7.
32. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. 2013. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29: 2238-44.
33. Zhao Y, Adjei AA. 2014. Targeting oncogenic drivers. Prog Tumor Res 41: 1-4.
34. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481: 306-13.
35. Garraway LA, Janne PA. 2012. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2: 214-26.
36. Hudson TJ, Anderson W, Artez A, Barker AD, et al. 2010. International network of cancer genome projects. Nature 464: 993-8.
37. The Cancer Genome Atlas Research Network. 2012. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-25.
38. Futreal PA, Coin L, Marshall M, Down T, et al. 2004. A census of human cancer genes. Nat Rev Cancer 4: 177-83.
39. Halling-Brown MD, Bulusu KC, Patel M, Tym JE, et al. 2012. CanSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 40: D947-D56.
40. Pagliarini R, Shao W, Sellers WR. 2015. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep 16: 280-96.
41. Epstein RJ. 2013. The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol 3: 304.
42. Amer MH. 2014. Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2: 27.
43. Buning H. 2013. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med 5: 1-3.
44. Kaufmann KB, Buning H, Galy A, Schambach A, et al. 2013. Gene therapy on the move. EMBO Mol Med 5: 1642-61.
45. Al-Dosari MS, Gao X. 2009. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 11: 671-81.
46. Atkinson H, Chalmers R. 2010. Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences. Genetica 138: 485-98.
47. Blaese RM, Culver KW, Miller AD, Carter CS, et al. 1995. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270: 475-80.
48. Porter DL, Levine BL, Kalos M, Bagg A, et al. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-33.
49. Kalos M, Levine BL, Porter DL, Katz S, et al. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
50. Brentjens RJ, Davila ML, Riviere I, Park J, et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
51. Perez OD, Logg CR, Hiraoka K, Diago O, et al. 2012. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20: 1689-98.
52. Huang TT, Parab S, Burnett R, Diago O, et al. 2015. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther 26: 82-93.
53. Huang TT, Hlavaty J, Ostertag D, Espinoza FL, et al. 2013. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther 20: 544-51.
54. Kim YS, Hwang KA, Go RE, Kim CW, et al. 2015. Gene therapy strategies using engineered stem cells for treating gynecologic and breast cancer patients (Review). Oncol Rep 33: 2107-12.
55. Blankenstein T, Leisegang M, Uckert W, Schreiber H. 2015. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 33: 112-9.
56. Hojjat-Farsangi M. 2015. Novel and emerging targeted-based cancer therapy agents and methods. Tumour Biol 36: 543-56.
57. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, et al. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-85.
58. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, et al. 2000. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 7: 588-92.
59. Nemunaitis J, Ganly I, Khuri F, Arseneau J, et al. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60: 6359-66.
60. O'Shea CC, Johnson L, Bagus B, Choi S, et al. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6: 611-23.
61. O'Shea CC, Soria C, Bagus B, McCormick F. 2005. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8: 61-74.
62. Heise C, Hermiston T, Johnson L, Brooks G, et al. 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-9.
63. Heise C, Sampson-Johannes A, Williams A, McCormick F, et al. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-45.
64. Kirn DH, Thorne SH. 2009. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
65. Roth JA, Grammer SF. 2003. Tumor suppressor gene therapy. Methods Mol Biol 223: 577-98.
66. Clayman GL. 1995. Gene therapy for head and neck cancer. Head Neck 17: 535-41.
67. Spitz FR, Nguyen D, Skibber JM, Cusack J, et al. 1996. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 16: 3415-22.
68. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, et al. 1994. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-91.
69. Kim J, Hwang ES, Kim JS, You EH, et al. 1999. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther 6: 172-8.
70. Pagliaro LC, Keyhani A, Liu B, Perrotte P, et al. 2003. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 21: 456-62.
71. Yang C, Cirielli C, Capogrossi MC, Passaniti A. 1995. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-3.
72. Peng Z. 2005. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16: 1016-27.
73. Schuler M, Herrmann R, De Greve JL, Stewart AK, et al. 2001. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 19: 1750-8.
74. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, et al. 2002. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9: 553-66.
75. Kuball J, Wen SF, Leissner J, Atkins D, et al. 2002. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 20: 957-65.
76. Lane DP, Cheok CF, Lain S. 2010. P53-based cancer therapy. Cold Spring Harb Perspect Biol 2: a001222.
77. Shimada H, Matsubara H, Shiratori T, Shimizu T, et al. 2006. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 97: 554-61.
78. Yoo GH, Moon J, Leblanc M, Lonardo F, et al. 2009. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 135: 869-74.
79. Cheok CF, Verma CS, Baselga J, Lane DP. 2011. Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
80. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-23.
81. He L, He X, Lim LP, de SE, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-4.
82. Wan G, Mathur R, Hu X, Zhang X, et al. 2011. MiRNA response to DNA damage. Trends Biochem Sci 36: 478-84.
83. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-31.
84. Zhang X, Lin L, Guo H, Yang J, et al. 2009. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res 69: 7960-8.
85. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83-96.
86. Wade M, Wahl GM. 2009. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1-1.
87. Fry DC, Graves B, Vassilev LT. 2005. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. Methods Enzymol 399: 622-33.
88. Vassilev LT, Vu BT, Graves B, Carvajal D, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of M DM2. Science 303: 844-8.
89. Tovar C, Graves B, Packman K, Filipovic Z, et al. 2013. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73: 2587-97.
90. Zak K, Pecak A, Rys B, Wladyka B, et al. 2013. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat 23: 425-48.
91. Zhang Q, Zeng SX, Lu H. 2014. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem 85: 281-319.
92. Freed-Pastor WA, Prives C. 2012. Mutant p53: one name, many proteins. Genes Dev 26: 1268-86.
93. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, et al. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-8.
94. Zandi R, Selivanova G, Christensen CL, Gerds TA, et al. 2011. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 17: 2830-41.
95. Lehmann S, Bykov VJ, Ali D, Andren O, et al. 2012. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30: 3633-9.
96. Brown CJ, Cheok CF, Verma CS, Lane DP. 2011. Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32: 53-62.
97. Gossage L, Eisen T, Maher ER. 2015. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55-64.
98. Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J. 1999. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell 4: 1051-61.
99. Frydman J, Nimmesgern E, Erdjument-Bromage H, Wall JS, et al. 1992. Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits. EMBO J 11: 4767-78.
100. Ding Z, German P, Bai S, Feng Z, et al. 2012. Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J Biomol Screen 17: 572-80.
101. Ding Z, German P, Bai S, Reddy AS, et al. 2014. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res 74: 3127-36.
102. Song MS, Salmena L, Pandolfi PP. 2012. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-96.
103. Combs AB, Acosta D. 1990. Toxic mechanisms of the heart: a review. Toxicol Pathol 18: 583-96.
104. Fyfe AJ, McKay P. 2010. Toxicities associated with bleomycin. J R Coll Physicians Edinb 40: 213-5.
105. McLornan DP, List A, Mufti GJ. 2014. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371: 1725-35.
106. Turner N, Tutt A, Ashworth A. 2004. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-9.
107. Antoniou A, Pharoah PD, Narod S, Risch HA, et al. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-30.
108. Begg CB, Haile RW, Borg A, Malone KE, et al. 2008. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299: 194-201.
109. Sonnenblick A, de AE, Azim HA, Jr., Piccart M. 2015. An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 12: 27-41.
110. Forster MD, Dedes KJ, Sandhu S, Frentzas S, et al. 2011. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 8: 302-6.
111. Sandhu SK, Schelman WR, Wilding G, Moreno V, et al. 2013. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14: 882-92.
112. Mendes-Pereira AM, Lord CJ, Ashworth A. 2012. NLK is a novel therapeutic target for PTEN deficient tumour cells. PLoS One 7: e47249.
113. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. 2007. P53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-89.
114. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, et al. 2009. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-909.
115. Cheung HW, Cowley GS, Weir BA, Boehm JS, et al. 2011. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108: 12372-7.
116. Nijhawan D, Zack TI, Ren Y, Strickland MR, et al. 2012. Cancer vulnerabilities unveiled by genomic loss. Cell 150: 842-54.
117. Muller FL, Colla S, Aquilanti E, Manzo VE, et al. 2012. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488: 337-42.
118. Vavouri T, Semple JI, Lehner B. 2008. Widespread conservation of genetic redundancy during a billion years of eukaryotic evolution. Trends Genet 24: 485-8.
119. Costanzo M, Baryshnikova A, Bellay J, Kim Y, et al. 2010. The genetic landscape of a cell. Science 327: 425-31.
120. DeLuna A, Vetsigian K, Shoresh N, Hegreness M, et al. 2008. Exposing the fitness contribution of duplicated genes. Nat Genet 40: 676-81.
121. Helming KC, Wang X, Wilson BG, Vazquez F, et al. 2014. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20: 251-4.
122. Smith DM, Fraga H, Reis C, Kafri G, et al. 2011. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell 144: 526-38.
123. Finley D. 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78: 477-513.
124. Kaneko T, Hamazaki J, Iemura S, Sasaki K, et al. 2009. Assembly pathway of the Mammalian proteasome base subcomplex is mediated by multiple specific chaperones. Cell 137: 914-25.
125. Liu Y, Zhang X, Han C, Wan G, et al. 2015. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520: 697-701.
126. Anderl J, Echner H, Faulstich H. 2012. Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology. Beilstein J Org Chem 8: 2072-84.
127. Letschert K, Faulstich H, Keller D, Keppler D. 2006. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91: 140-9.
128. Faulstich H, Fiume L. 1985. Protein conjugates of fungal toxins. Methods Enzymol 112: 225-37.
129. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, et al. 2012. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104: 622-34.